Sandra Sánchez, General Manager at PROBIOMED, explains the crucial role that biosimilars will play in the future healthcare system as well as the importance of complying with COFEPRIS’ regulations to expand PROBIOMED’s business within the region.
Last time we met with you, you explained that PROBIOMED was following a three tier-strategy: first, meeting the new COFEPRIS’ requirements, second, establishing corporate governance, third, global expansion, and fourth, accelerating the development of the five products you had in your pipeline. Two years later, what would highlight as your main achievements?
We are working closely with COFEPRIS to make sure we meet every single requirement by the end of 2017
